Development of new treatment modalities for atopic dermatitis

Development of new treatment modalities for atopic dermatitis

Authors	E.J.M. van Leent
Supervisors	J.D. Bos
Cosupervisors	J.H. Sillevis Smitt
Award date	13-11-2002
Number of pages	212
Organisations	Faculty of Medicine (AMC-UvA)
Document type	PhD thesis
Note	Research conducted at: Immunologie
Language	English
Downloads	Thesis Cover Titlepage CONTENTS Chapter 1A Introduction to Atopic Dermatitis Chapter 1B Introduction to development of new treatment modalities and aims of the studies Chapter 2 The millennium criteria for the diagnosis of atopic dermatitis Chapter 3 Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic Dermatitis Chapter 4 SDZ ASM 981 : an emerging safe and effective treatment for atopic dermatitis Chapter 5 Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis Chapter 6 Long-term pharmacokinetics of pimecrolimus (SDZ ASM 981, Elidel®) in atopic dermatitis Chapter 7 In contrast to pimecrolimus (Elidel®, SDZ ASM 981), the ascomycin derivative SDZ ASD 732 is not effective in atopic dermatitis Chapter 8 Safety and Efficacy of 1 Year of Tacrolimus Ointment Monotherapy in Adults With Atopic Dermatitis Chapter 9 Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis Chapter 10 Randomised comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream in atopic dermatitis Chapter 11 Medium dose long wave ultraviolet A (UVA1) provided by fluorescent tubes is effective and safe as treatment for severe atopic dermatitis Chapter 12 SUMMARY AND CONCLUSIONS Chapter 13 SAMENVATTING EN CONCLUSIE Chapter 14 Dankwoord Chapter 15 Publications Stellingen Cover
Permalink to this page

Back

UvA-DARE

Digital Academic Repository

Development of new treatment modalities for atopic dermatitis